The first drug to treat sexual dysfunction in premenopausal women - dubbed the “female Viagra” - has received approval for the U.S. market
Manufactured by Sprout Pharmaceuticals, Addyi has been approved by the Food and Drug Administration for the treatment of hypoactive sexual desire disorder (HSDD) - a condition characterized by low sexual desire. According to sexual health studies, an estimated 1 in 10 women develop HSDD, and up to 40% experience the condition at some point in their lives. While the exact mechanisms by which Addyi works is unclear, Sprout Pharmaceuticals believe it corrects an imbalance in brain chemicals that are responsible for sexual desire.The development of the drug comes nearly 65 years after the first female contraceptive was approved by the FDA in 1960.
While male sexual dysfunction drugs have been widely available for years- the long awaited creation of a female counterpart has been widely celebrated as revolutionary. Dr Lauren Streicher, associate professor of clinical obstetrics and gynecology at Northwestern University said in a interview with Medical News; “This is an enormous advance in women’s health. Of all the sexual dysfunctions, this is by far the most common in every single age category and we’ve had no options for women up until now.”